Prompt referral for myocardial reperfusion represents the gold standard emergency treatment for patients experiencing ST-elevation myocardial infarction ( STEMI). However, in a considerable proportion o f STEMI patients, reopening of the infarct-related artery is not always followed by myocardial reperfusion. This condition is known as no-reflow and seems to be related to microvascular obstruction. Interestingly, no-reflow has been observed also in NSTEMI patients and during elective percutaneous coronary intervention, particularly when performed on saphenous vein grafts. Distal atherothrombotic embolisation has a key role in no-reflow physiopathology. In this revie w we will summarise available evidence concerning the most important nonpharmacological procedural strategies tested in a clinical setting to prevent distal embolisation and, thus, no-reflow during per cutaneous coronary intervention. 
Introduction
Prompt referral for mechanical (primary percutaneous coronary intervention [pPCI] ) or pharmacological (fibrinolytic) reperfusion represents the gold standard emergency treatment for patients experiencing STelevation myocardial infarction (STEMI) [1] [2] [3] . However, in a considerable proportion of STEMI patients, successful restoration of infarct-related artery (IRA) patency is not followed by adequate myocardial blood flow at a tissue level. This condition is known as noreflow and seems to be related to microvascular obstruction (MVO) [4] . No-reflow represents one of the most challenging conditions for interventional cardiologists and has a strong negative impact on in-hospital and long-term clinical o utcome o f STEMI patients treated with pPCI or fibrinolysis, negating the benefits of prompt and effective reopening of the IRA [5] [6] [7] [8] [9] [10] . Interestingly, no-reflow has been observed a lso in NSTEMI patients and during elective PCI, particularly when performed on saphenous vein grafts [11] .
No-reflow can be assessed with both invasive and noninvasive techniques. On the basis of coronary angiography, no-reflow is usually defined as a Thrombolysis in Myocardial Infarction (TIMI) flow grade <3 or 3 in the presence of a myocardial blush grade (MBG) 0 to 1 despite effective mechanical or pharmacological restoration of IRA patency [12, 13] . In the setting of STEMI, an ST-segment elevation resolution of less than 70% 60 to 90 minutes after pPCI on the surface electrocardiogram (ECG) is usually considered suggestive of noreflow [14] . Myocardial c ontrast echocardiography (MCE) uses ultra sound to visualise contrast microbubbles that freely flow within patent microcirculation; no-reflow is detected as lack of intramyocardial reversible reduction in myocardial blood flow when microspheres obstruct more than 50% of coronary capillaries [17] . Large emboli (with a diameter >200 µm) are the most likely to significantly obstruct pre-arterioles and, therefore, reduce myocardial blood flow at a tissue level [17, 18] .
In this review we will summarise the most important predictors of no-reflow related to distal embolisation, as well as available evidence concerning the most important nonpharmacological procedural strategies to preven t distal embolisation and, thus, no-reflow during PCI. As a result of the multifactorial physiopathology of no-reflow, multiple pharmaco logical agents specifically targeting different physiopathological pathways, such as antiplatelet and vaso dilator drugs, have also been tested for prevention of no-reflow, especially in the setting of STEMI. However, a systematic and comprehensive review of the use of pharmacological agents to prevent no-reflow is beyond the scope of the present article.
Procedural predictors of distal embolisation-related no-reflow
Several parameters have been shown to be able to predict no-reflow occurrence probably owing, at least in part, to their ability to predict distal embolisation during PCI.
Coronary angiography allows direct visualisation of luminal thrombus on culprit coronary stenosis. Prethrombectomy/pre-pPCI features of luminal thrombus as assessed with coronary angiography predict noreflow occurrence in STEMI patients undergoing pPCI [19] . Interestingly, i n STEMI patients u ndergoing mechanical thrombectomy as a djunct t o standard pPCI, a high residual thrombus burden after thrombectomy has also been recently demonstrated to independently predict post-pPCI no-reflow occurrence [20] .
Moreover, a reference lumen diameter bigger than 4 mm was an independent predictor of no-reflow in a study by Yip et al. [19] . In a recent large retrospective registry of acute coronary syndrome patients, PCI on bifurcation coronary lesions and PCI on complex coronary lesions as assessed with coronary angiography were both associated with higher no-reflow risk, probably due to a high risk of distal embolisation from coro nary culprit plaque. However, both NSTEMI and STEMI patients were included in this registry [21] . Coronary angiography also allows prediction of distal embolisation and no-reflow during e lective PCI p er- This association was not confirmed in a more recent study by Ikenaga et al. in 39 STEMI patients. In this study the longitudinal length of the lipid pool was found to be the only OCT predictor of no-reflow [28] . Interestingly, IVUS and OCT data seem to be able to predict no-reflow occurence mainly due to an increased risk of distal embolisation from coronary plaque.
In a recent study by Carol et al. on STEMI patients, late clinical presentation (i.e., first medical contact >12 hours after symptom onset) was associated with a higher p revalence of old o rganised t hrombus on patho logical analysis after thrombus-aspiration during pPCI [29] . Organised thrombus is known to be an independent predictor of both in-hospital and longterm mortality in STEMI patients undergoing pPCI [30] [31] . Moreover, organised thrombus, as compared with fresh thrombus, was associated with a higher risk of macroscopic distal embolisation during angiography and with a lower rate of complete ST segment resolution after pPCI in a recent study by Verouden et al.
[32]. This could explain, at least in part, the high risk of no-reflow observed in late-presenting STEMI patients.
CARDIOVASCULAR MEDICINE -KARDIOVASKULÄRE MEDIZIN -MÉDECINE CARDIOVASCULAIRE 2016;19(7-8): [197] [198] [199] [200] [201] [202] [203] Interestingly, increased risk of severe ischaemic-and reperfusion-related injury could also contribute to the high risk of no-reflow observed in this subgroup of STEMI patients. Therefore, prompt referral for reperfusion with reduction of ischaemia time surely represents a key strategy to prevent no-reflow occurrence, reduce infarct size and allow myocardial salvage in STEMI patien ts.
Management of distal embolisation to prevent no-reflow
As s een before, distal e mbolisation f rom coronary thrombus or plaque has a key role in no-reflow physiopathology. M ultiple n onpharmacological procedural strategies have been tested in a clinical setting in an effort to prevent distal embolisation and, thus, no-reflow.
Thrombectomy devices
The use of manual or mechanical thrombectomy devices to reduce the risk of distal embolisation during pPCI has been investigated in several clinical trials.
Manual thrombectomy is usually performed using dedicated catheters compatible with a 6 or 7 French guiding catheter on 0.014'' guide-wires and allows di- 
Distal protection devices
Distal protection devices used in the setting of PCI essentially consist of a filter device placed between the target lesion and the distal vasculature ( fig. 2) . Filterbased distal protection devices allow blood flow during PCI and prevent distal migration of microparticles whose diameter is greater than pore size (usually 100- 
Excimer coronary laser
The excimer coronary laser involves a laser beam in the field of ultraviolet (308 nm). The absorption depth is of 0.05 mm, thus allowing a very short space of action. Current laser catheters may be concentric or eccentric according to the laser beam orientation, and 
MGuard® and MGuard Prime® stents
MGuard® ( flow. In these meta-analyses direct stenting was also associated with a significant reduction in short-term and 1-year mortality, although these data were mostly derived retrospectively from small clinical registries rather than randomised controlled trials [59, 60] .
In conclusion, available evidence supports direct stenting to prevent no-reflow in STEMI patients. However, only a specific subset of patients (those with optimal distal visualisation of the IRA after guidewire passage)
is suitable for this technique in order to avoid stent undersizing.
Deferred stenting
The DEFER-STEMI trial recently compared d eferred stenting (intention-to-stent 4 to 6 hours after balloon angioplasty) with immediate stenting for no-reflow prevention in pPCI. A total of 101 STEMI patients were enrolled. Deferred stenting was significantly associated with lower no-reflow/slow-reflow rates and an increased myocardial salvage index at 6 months, but also with a potentially increased risk of recurrent STEMI [61] . Results from the DEFER-STEMI trial are provocative, but clinical benefits on both no-reflow occurrence and prognosis in STEMI patients as well as the safety of deferred stenting (risk of bail-out stenting)
should be confirmed in trials on larger populations.
Conclusions
Distal atherothrombotic coronary embolisation plays a key role in no-reflow physiopathology and multiple nonpharmacological procedural strategies have been tested in clinical practice in order to prevent distal embolisation and, thus, reduce no-reflow occurrence.
In the setting of pPCI direct stenting should be prefer- 
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